Osteoporosis in Medical Technology

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

... Food and Drug Administration for the treatment of osteoporosis in women and men at high risk of fracture. ... are one of the most serious complications of osteoporosis and an area in which currently available osteoporosis treatments are weak." "These data are ...

Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease

... than 340,000(2) women suffer from postmenopausal osteoporosis (PMO) in Ohio and more than 900,000(3) are at ... n=912 without PMO) that many women suffering from osteoporosis are not optimally managing their disease despite ... risk for fracture. According to the National osteoporosis Foundation fracture may lead to chronic pain, ...

CVS Caremark Data Confirms Improved Outcomes for Women with Osteoporosis Who are Adherent to Therapy

... Caremark data also found that those women with osteoporosis between the ages of 18-64 who were not on therapy ... ) According to the National osteoporosis Foundation (NOF), approximately eight million women in the U.S. have osteoporosis and an additional 27.2 million women are ...

Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density

... being studied for the prevention and treatment of osteoporosis in postmenopausal women and the reduction of risk ... breast cancer in postmenopausal women with osteoporosis or low bone mass. These data are from the ... Society for Clinical and Economic Aspects of osteoporosis and Osteoarthritis (ECCEO) annual meeting. The ...

Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis

... from a large clinical study on the genetics of osteoporosis and vertebral fractures at the 8th International ... of Inflammatory Gene Variants as Biomarkers of osteoporosis Risk in Asian Women," highlights genetic ... in Asian women for vertebral fractures and osteoporosis and will be presented at 9:45 a.m. in Exhibit ...

Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis

... versus Raloxifene in Postmenopausal Women with osteoporosis ATHENS, Greece, March 23 ... Society for Clinical and Economic Aspects of osteoporosis and Osteoarthritis (ECCEO) annual meeting. ... being studied for the prevention and treatment of osteoporosis in postmenopausal women and the reduction of risk ...

Staying One Step Ahead of Osteoporosis

... Feb. 26 /PRNewswire-USNewswire/ -- Facts about osteoporosis are staggering. 75 million baby boomers are ... disease is tightening its grip on their bones. osteoporosis ( ... Irvine's College of Medicine. "If we screen for osteoporosis at the earliest onset of the disease," said Dr. ...

Applying Clinical Findings to the Practice of Medicine

... ) osteoporosis ( ... insertion," stated Dr. Thomopoulos. osteoporosis and Osteoarthritis Hiroshi Kawaguchi, MD, ... disorders, like debilitating conditions such as osteoporosis and osteoarthritis, which are suffered by ...

American Academy Of Orthopaedic Surgeons 2009 Annual Meeting 'Highlights and Hot Topics'

... Treatment Using Balloons Appears Effective for osteoporosis Fractures ( ... are shown to add improved activity for osteoporosis patients People with osteoporosis often endure spinal fractures that are painful ...

Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds

... California who had specific risk factors for osteoporosis and/or hip fractures. The implementation of a ... role is taken by all orthopedic surgeons in osteoporosis disease management." The National osteoporosis Foundation reports that although osteoporosis can ...

Lilly and TransPharma Medical Announce Licensing and Development Agreement

... "This agreement expands the scope of our osteoporosis program with a novel, patient-centered approach ... to partner with Lilly, a leading player in the osteoporosis market," said Dr. Daphna Heffetz, CEO of ... peptides and proteins. About Osteoporosis osteoporosis is a debilitating disease that affects an ...

FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture

... fracture(1) - Few patients currently receive osteoporosis treatment following hip fracture despite ... had a low-trauma hip fracture(1). No other osteoporosis treatment has demonstrated a reduction of ... treated with Reclast(3). "The consequences of osteoporosis can be devastating, particularly hip fractures. ...

Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis

... fracture." About Osteoporosis osteoporosis is a disease characterized by low bone mass and ... of fractures. According to the National osteoporosis Foundation, the number of women of menopausal age who have osteoporosis or are at risk for developing the disease will ...

Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids

... of glucocorticoid-induced osteoporosis in US EAST HANOVER, N.J., April 11 /PRNewswire/ ... at increasing bone mass in patients with osteoporosis caused by glucocorticoids, commonly known as ... approved for the treatment of postmenopausal osteoporosis and for the treatment of Paget's disease of bone ...

Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis

... of BA058 to build new bone for the treatment of osteoporosis in postmenopausal women. Radius also announced ... 244 otherwise healthy postmenopausal women with osteoporosis at 35 centers in the United States, United ... a next-generation bone anabolic treatment for osteoporosis that promises to build bone more rapidly and ...

FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis

... that in patients with glucocorticoid-induced osteoporosis FORTEO(R) (PTH 1-34, teriparatide [rDNA origin] ... that rebuilds bone in postmenopausal women with osteoporosis who are at high risk for fracture and increases bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.(5,6) ...

Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble

... PTH1-34) nasal spray for the treatment of osteoporosis from its collaboration partner, Procter & ... conduct a Phase 2 clinical study in patients with osteoporosis to examine the effect of PTH1-34 Nasal Spray on ... are approved for the treatment of postmenopausal osteoporosis and generated $594 million in sales during 2006. ...

New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis

... group were considered treatment related. About osteoporosis osteoporosis (porous bones) is a disease in which bones become ... osteoporosis. Unfortunately, the prevalence of osteoporosis is growing, especially as the number ...

Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis

... both bazedoxifene doses were combined. About osteoporosis According to the National osteoporosis Foundation, the number of women of menopausal age who have osteoporosis or are at risk for developing the disease will ...

New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis

... monthly for the treatment of postmenopausal osteoporosis were presented at the American Society for Bone ... McClung, M.D., Founding Director of the Oregon osteoporosis Center in Portland, Oregon. "For patients who ... is approved for the prevention and treatment of osteoporosis in postmenopausal women. Actonel has been proven ...

First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival

... with Reclast -- Few patients currently receive osteoporosis treatments following hip fracture despite ... -- Results of the first ever clinical study in osteoporosis patients who have had a hip fracture show that a ... group (101 versus 141 deaths, respectively). osteoporosis patients with hip fractures may face devastating ...

FDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women

... and Drug Administration (FDA) has approved its osteoporosis drug EVISTA(R) (raloxifene HCl) for a new use to ... in two populations: postmenopausal women with osteoporosis and postmenopausal women at high risk for ... For the first time, postmenopausal women with osteoporosis will have one treatment option that can help ...

Raptor Pharmaceuticals Provides Update of Product Programs

... Preclinical Testing Completed for WntTide(TM) in osteoporosis Raptor has completed preclinical testing of ... in increasing bone density in the treatment of osteoporosis and rheumatoid arthritis. The Company has run ... a known determinant of bone density, to combat osteoporosis and increase bone density. In an effort to ...

Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis

... a full year's protection against the effects of osteoporosis -- a disorder that causes bones to break easily. ... patients a choice when it comes to taking their osteoporosis therapy." Reclast/Aclasta is approved in more ... is recommended that patients with postmenopausal osteoporosis take calcium and vitamin D supplements, ...

Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes

... SERMS are approved for the treatment and prevention of breast cancer and osteoporosis but tend to respectively increase the frequency and severity of hot ... in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $106.5 million in private equity ...

Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million

... position, with a broad and maturing portfolio of drug candidates for osteoporosis and women's health, an option agreement with a major pharmaceutical ... in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $106.5 million in private equity ...

Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment

... study will be conducted in North and South America, Europe and Asia. osteoporosis is a disease associated with a gradual thinning and weakening of the ... bones are increasingly susceptible to fractures. Untreated postmenopausal osteoporosis can lead to chronic back pain, disabling fractures, and lost mobility. ...

Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)

... estimated to yield first interpretable results by the end of the year. osteoporosis is a disease associated with a gradual thinning and weakening of the ... bones are increasingly susceptible to fractures. Untreated postmenopausal osteoporosis can lead to chronic back pain, disabling fractures, and lost mobility. ...

Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture

... of disease," said Michael McClung, M.D., Founding Director of the Oregon osteoporosis Center in Portland and a primary investigator of the study. "In this ... risk among patients with severe osteoporosis." According to the National osteoporosis Foundation, a history of prior fracture is an important risk factor for ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... *Editors Note: The FDA has provisionally approved the trade name Prolia(TM) for the proposed indications of treatment and prevention of osteoporosis in postmenopausal women, and treatment and prevention of bone loss in patients undergoing hormone ablation for prostate or breast cancer. The ...

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

... between BZA/CE and placebo. 4. Efficacy of Tissue-Selective Estrogen Complex (TSEC) of Bazedoxifene/Conjugated Estrogens (BZA/CE) for osteoporosis Prevention in At-Risk Postmenopausal Women (Lindsay R, et al) When compared with placebo, treatment with BZA/CE increased BMD at the lumbar ...

July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals

... number of Americans are deficient in vitamin D. It's been well established that adequate vitamin D and calcium can prevent or slow osteoporosis and reduce bone fractures. New research highlights other potential benefits of vitamin D, including reducing the risk of muscle pain and weakness, ...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

... *Editors Note: The FDA has provisionally approved the trade name Prolia(TM) for the proposed indications of treatment and prevention of osteoporosis in postmenopausal women, and treatment and prevention of bone loss in patients undergoing hormone ablation for non-metastatic prostate or breast ...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin, osteoporosis and may contribute to shortening life expectancy by affecting major organ systems. After 10 years, less than 50 percent of patients can continue to ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

... hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin, osteoporosis and may contribute to shortening life expectancy by affecting major organ systems. After 10 years, less than 50 percent of patients can continue to ...

AAOMS Updates BRONJ Position Paper

... for cancer-related conditions and BRONJ, the 2009 BRONJ Position Paper stresses that the relationship between oral or IV bisphosphonates for treating osteoporosis and BRONJ is more difficult to establish. Specifically, the 2009 BRONJ Position Paper observes that the risk of developing BRONJ is linked to: ...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

... hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin, osteoporosis and may contribute to shortening life expectancy by affecting major organ systems. After 10 years, less than 50 percent of patients can continue to ...

Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials

... for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA ...

Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study

... diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit ...

Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions

... ABOUT RADIUS (http://www.radiuspharm.com ) Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $91.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, ...